Ipsen announced plans to acquire Memo Therapeutics for €700 million (about $797 million), bringing potravitug, a Phase 2/fast-track antibody targeting BK virus-associated infections in kidney transplant patients with nephropathy. Ipsen framed the deal as rare-disease expansion, with potravitug expected to move into a pivotal Phase 2/3 trial later this year based on prior viral load and biopsy-proven nephropathy results. The transaction also included a corporate restructure, with non-potravitug assets spun into a new entity owned by Memo shareholders.